Skip to main content
. Author manuscript; available in PMC: 2013 Mar 1.
Published in final edited form as: Biochim Biophys Acta. 2011 Sep 25;1821(3):365–372. doi: 10.1016/j.bbalip.2011.09.008

Figure 5.

Figure 5

The change in coronary stenosis during combination drug and placebo therapy in FATS is related to the change in LDL peak buoyancy: an increase in LDL buoyancy is associated with less coronary stenosis. Patients with FCHL and elevated Lp(a) treated with combination therapy had and increase in buoyancy, while those with hFH did not. Includes subjects treated with placebo. Modified from [14].